Tharimmune, Inc. (NASDAQ:THAR) Short Interest Update

Tharimmune, Inc. (NASDAQ:THAR) saw a significant decrease in short interest in the month of March. As of March 15th, there was short interest totalling 30,200 shares, a decrease of 16.8% from the February 28th total of 36,300 shares. Approximately 1.6% of the company’s shares are short sold. Based on an average daily volume of 64,800 shares, the short-interest ratio is currently 0.5 days.

Institutional Investors Weigh In On Tharimmune

A hedge fund recently bought a new stake in Tharimmune stock. Virtu Financial LLC bought a new position in Tharimmune, Inc. (NASDAQ:THAR) during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor bought 21,371 shares of the company’s stock, valued at approximately $44,000. Virtu Financial LLC owned 1.11% of Tharimmune at the end of the most recent reporting period. Institutional investors own 1.16% of the company’s stock.

Tharimmune Stock Up 10.2 %

Shares of NASDAQ:THAR traded up $0.13 on Wednesday, hitting $1.41. The company had a trading volume of 9,837 shares, compared to its average volume of 356,196. The firm’s 50-day simple moving average is $1.69 and its two-hundred day simple moving average is $2.07. The firm has a market capitalization of $2.73 million, a price-to-earnings ratio of -0.14 and a beta of 1.28. Tharimmune has a 1 year low of $1.20 and a 1 year high of $7.46.

Tharimmune (NASDAQ:THAR) last issued its quarterly earnings data on Tuesday, March 25th. The company reported ($2.02) EPS for the quarter.

Analysts Set New Price Targets

THAR has been the subject of a number of recent analyst reports. RODMAN&RENSHAW raised Tharimmune to a “strong-buy” rating in a research report on Friday, December 6th. Rodman & Renshaw assumed coverage on Tharimmune in a research note on Friday, December 6th. They set a “buy” rating and a $17.00 target price on the stock.

Tharimmune Company Profile

Tharimmune, Inc, a clinical-stage biotechnology company, engages in the development of therapeutic candidates for rare, inflammatory, and oncologic diseases. The company's pre-clinical immuno-oncology pipeline includes TH104, a product candidate for the treatment of liver-related and other pruritogenic inflammatory conditions; TH3215 and TH0059 that are product candidates used to treat various solid tumors; and TH1940, which targets programmed cell death protein 1 (PD-1).